Postgraduate Program in Structural and Functional Interactions in Rehabilitation, University of Marília (UNIMAR), Marília, Brazil.
Department of Biochemistry and Pharmacology, School of Medicine, University of Marília (UNIMAR), Marília, Brazil.
J Med Food. 2021 Jul;24(7):675-685. doi: 10.1089/jmf.2020.0129. Epub 2020 Nov 5.
Inflammatory bowel disease (IBD) is an umbrella term used to describe chronic inflammatory disorders related to a substantial reduction in the quality of life of patients. Some patients with Crohn's disease (CD) and ulcerative colitis (UC) are refractory to conventional therapies, and derivatives have been considered as adjuvants. Owing to the anti-inflammatory and antioxidant effects, some clinical trials used this plant in the therapeutic approach of IBD, and some meta-analyses evaluated the outcomes found in these studies. Owing to controversial findings, our systematic review aimed to evaluate these studies to show whether compounds can still be considered in the therapeutic approach of patients with CD and UC. MEDLINE-PubMed, EMBASE, and Cochrane were searched, and Preferred Reporting Items for a Systematic Review and Meta-Analysis guidelines were followed. The results of the randomized clinical trials (RCTs) showed promising results with the use of curcumin in the therapeutic approach of both UC and CD patients. Some meta-analyses show controversial results, possibly due to the presence of bias in the included studies. The actions of curcumin are achieved by several mechanisms, such as reducing the expression of interleukin (IL)-1, IL-6, IL-12, and tumor necrosis factor-. Moreover, it reduces the levels of reactive oxygen species, such as superoxide anions and malondialdehyde. The results of using curcumin in CD and UC patients are challenging to be evaluated because RCTs are variable in the dose and the formulations of curcumin, in the time of treatment, and the route of administration. The number of patients in the samples is also usually small.
炎症性肠病（IBD）是一个总称，用于描述与患者生活质量大幅下降相关的慢性炎症性疾病。一些克罗恩病（CD）和溃疡性结肠炎（UC）患者对常规治疗无效，因此被认为是辅助治疗。由于具有抗炎和抗氧化作用，一些临床试验将这种植物用于 IBD 的治疗方法中，一些荟萃分析评估了这些研究中的结果。由于存在争议，我们的系统评价旨在评估这些研究，以表明姜黄素化合物是否仍可用于 CD 和 UC 患者的治疗方法中。我们检索了 MEDLINE-PubMed、EMBASE 和 Cochrane，并遵循了系统评价和荟萃分析报告的首选条目。随机临床试验（RCT）的结果显示，姜黄素在 UC 和 CD 患者的治疗方法中具有有希望的结果。一些荟萃分析的结果存在争议，可能是由于纳入研究中存在偏倚。姜黄素的作用是通过多种机制实现的，例如降低白细胞介素（IL）-1、IL-6、IL-12 和肿瘤坏死因子-α的表达。此外，它还降低了活性氧物质（如超氧阴离子和丙二醛）的水平。由于 RCT 在姜黄素的剂量和配方、治疗时间和给药途径方面存在差异，并且样本中的患者数量通常较少，因此评估姜黄素在 CD 和 UC 患者中的使用结果具有挑战性。
